Emerging clinical evidence suggests epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs), either alone or in combination with other therapies, such as chemotherapy, radiotherapy, or immunotherapy (e.g., nivolumab or pembrolizumab), have shown promise as targeted regimens for head and neck cancers, including oral cancers [4,5]. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.